APOE and Alzheimer disease: This is evidenced by failures in phase III clinical trials of drugs designed to treat Alzheimer’s disease (AD) that target genes in the APOE gene pathway (Amanatkar et al. 2017; Sperling et al. 2011; Sperling et al. 2013).